GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » EBIT

Acepodia (ROCO:6976) EBIT : NT$-811.70 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Acepodia EBIT?

Acepodia's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was NT$-617.14 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$-811.70 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Acepodia's annualized ROC % for the quarter that ended in Jun. 2023 was -148.83%. Acepodia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -580.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Acepodia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -9.95%.

Acepodia EBIT Historical Data

The historical data trend for Acepodia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia EBIT Chart

Acepodia Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
-454.90 -877.72 -1,412.85 -811.70

Acepodia Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial - 78.92 -1,491.77 -617.14 -194.56

Competitive Comparison of Acepodia's EBIT

For the Biotechnology subindustry, Acepodia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acepodia's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acepodia's EV-to-EBIT falls into.


Acepodia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-811.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acepodia  (ROCO:6976) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Acepodia's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-396.654 * ( 1 - 0% )/( (132.603 + 400.436)/ 2 )
=-396.654/266.5195
=-148.83 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3872.551 - 83.409 - ( 3726.644 - max(0, 125.752 - 3782.291+3726.644))
=132.603

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7016.731 - 44.288 - ( 6634.89 - max(0, 88.711 - 6660.718+6634.89))
=400.436

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Acepodia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1234.27/( ( (83.501 + max(-90.242, 0)) + (341.463 + max(-35.355, 0)) )/ 2 )
=-1234.27/( ( 83.501 + 341.463 )/ 2 )
=-1234.27/212.482
=-580.88 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 24.604) - (83.409 + 0 + 31.437)
=-90.242

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 25.526) - (44.288 + 0 + 16.593)
=-35.355

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Acepodia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-811.699/8155.227
=-9.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acepodia EBIT Related Terms

Thank you for viewing the detailed overview of Acepodia's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia (ROCO:6976) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » EBIT
Comparable Companies
ROCO:4174 ROCO:6617 ROCO:4162 ROCO:6712 ROCO:4147 ROCO:6586 ROCO:6547 ROCO:6919 TPE:4142 ROCO:4157 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175
Website
https://www.acepodia.com
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines